Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG318 CAR-T in Adults With Refractory Inflammatory Bowel Disease
NCT07544160Phase 2Not yet recruiting
- Sponsor
- iCell Gene Therapeutics
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ICG318 in inflammatory bowel disease (IBD), sponsored by iCell Gene Therapeutics. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ICG318
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07544160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544160.